2012/3-4 GaBI Journal Table of Contents

Published in: Volume 1 / Year 2012 / Issue 3-4
Category: 2012/3-4 GaBI Journal Table of Contents
Visits: 2376 total, 1 today


Editor’s Letter

Latest features in GaBI Journal, 2012, issue 3-4

Letters to the Editor

A bioethicist’s view of the use of biosimilars

A clinician’s view of the ethics of the use of biosimilars


Generics policies–a globally-relevant implementation challenge

Reference price systems: stakeholder dialogue and involvement


Statin generics: no differences in efficacy after switching

Pharmacovigilance of biosimilars: challenges and possible solutions

Original Research

Saving money in the European healthcare systems with biosimilars

Review Article

Reference pricing systems in Europe: characteristics and consequences


Terminology for biosimilars–a confusing minefield

Health professionals in the risk communication process on counterfeit medicines

Special Report

The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes


ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities

Conference Report

The potential of generics policies: more room for exploitation–PPRI Conference Report


Austria could save Euros 256 million by using more generics

Abstracted Scientific Content

The potential for doctors to contribute to biosimilar guidelines


Go Back Print

Leave a Reply